Retatrutide is an experimental triple hormone receptor agonist developed by Eli Lilly. It simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, slow digestion, improve insulin response, and increase energy expenditure/fat burning—aiming for more potent effects than dual-agonist drugs like tirzepatide.
Administered as a once-weekly injection, it has shown impressive results in clinical trials for obesity (and related conditions like type 2 diabetes or knee osteoarthritis).
In the Phase 3 TRIUMPH-4 trial (announced December 2025), participants achieved up to an average 28.7% body weight loss (about 71 lbs) at the highest 12 mg dose over 68 weeks, plus major reductions in knee pain and improved function. Other Phase 3 data and earlier Phase 2 studies reported losses around 24–29% at higher doses over similar periods.
It's not yet FDA-approved (as of February 2026) and remains investigational, with several more Phase 3 trials (in the TRIUMPH program) expected to read out throughout 2026. Approval could potentially come in late 2026 or 2027 if results stay positive.
For research use only - Not for human consumption - 18+ only
10 In Stock
